Information  X 
Enter a valid email address

Creo Medical Group (CREO)

  Print      Mail a friend

Tuesday 12 March, 2019

Creo Medical Group

Speedboat in BSG Endoscopy best video abstract

RNS Number : 5914S
Creo Medical Group PLC
12 March 2019
 

Creo Medical Group plc

("Creo" or the "Company")

 

Speedboat features in BSG Endoscopy Live 2019 best video abstract

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that the Company's Speedboat device was the key subject of the winner of "The Best Video Abstract" during last week's BSG Endoscopy Live 2019 conference in Gateshead. The presentation, "Endoscopic submucosal dissection with the 'Speedboat RS2 device'; a multi-modality device", was delivered to this gathering of prestigious faculty of UK and international endoscopists, and conference delegates.

 

The abstract was written by UK experts in the field of Gastrointestinal ("GI") therapeutic endoscopy and users of Creo's Speedboat device for colorectal endoscopic submucosal dissection, an advanced surgical procedure using endoscopy to remove gastrointestinal pre-cancerous lesions that have not entered the muscle layer. The authors were:

 

-      Professor Brian Saunders, Consultant Gastroenterologist at St. Mark's Hospital Foundation

-      Dr Zacharias Tsiamoulos, Consultant Gastroenterologist at Queen Elizabeth the Queen Mother Hospital, East Kent

-      Dr Ioannis Stasinos, Endoscopy Research Fellow at St. Mark's Hospital Foundation, London

 

Endoscopy Live 2019 was the 3rd national live endoscopy meeting organised by the BSG and was held at the Sage Gateshead on 7 and 8 March, showcasing advances in UK Endoscopy and bringing together consultant gastroenterologists from across the UK, trainees interested in gastroenterology, surgical colleagues and nurses.

 

Craig Gulliford, Chief Executive Officer of Creo, commented:

"For the authors to win the best video abstract at such a key scientific meeting is another important step in the recognition and momentum that is being generated by the clinical use of the Speedboat Device. It was clear throughout the presentation of the video abstract that the Speedboat technology provided precise dissection and controlled haemostasis with a single device, which shows the potential of the technology to simplify these procedures for the clinical team and most importantly generate effective patient outcomes. This was all the more fitting as a key theme of the meeting was how using technology can make difficult therapeutic endoscopy simpler."

 

 

Creo Medical Group plc

 

Richard Rees (CFO)

+44 (0)129 160 6005

 

 

Cenkos Securities

+44 (0)20 7397 8900

Stephen Keys / Mark Connelly (NOMAD)

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Helen Cresswell

Mob: +44 (0)7841 917 679

 

 



 

About Creo Medical

 

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions.

 

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

 

For more information about Creo Medical please see our website, investors.creomedical.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRALIFLAVRIFLIA

a d v e r t i s e m e n t